CGRP mAb Subcutaneous denied as not FDA-approved for this use by Cigna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on CGRP mAb Subcutaneous
## Why Cigna Issued a Not-FDA-Approved Denial for Your CGRP Monoclonal Antibody
A not-FDA-approved denial from Cigna signals that the plan's review concluded the drug lacks FDA approval for the indication listed in the prior-authorization request. For CGRP monoclonal antibodies, this typically arises in one of two situations: (1) the ICD-10 code submitted on the PA form corresponds to a condition for which this specific agent does not yet carry FDA approval (for example, an off-label pain syndrome), or (2) there was a coding or administrative error in the submission and the approved indication was never matched to the request.
## Why This Denial Is Appealable
If your prescriber is treating you for an indication that is on the FDA-approved label, the denial rests on a factual error and can be corrected by submitting the current FDA prescribing information alongside a corrected PA. If the use is genuinely off-label, the appeal must demonstrate that the use is supported by published evidence and recognized by an applicable professional society — many plans are required to cover off-label uses with this level of evidence support, particularly under plans subject to state insurance mandates.
## Your Federal Appeal Rights
- ACA §2719 external review is available if internal appeal is denied; the window is generally approximately four months after final internal denial. An external independent reviewer will assess FDA status and evidentiary support independently.
- ERISA §503 requires a full-and-fair written review for self-funded plans.
- Request expedited processing if the patient's condition is unstable or rapidly worsening.
## Documentation to Gather
- FDA prescribing label: download the current label from DailyMed (dailymed.nlm.nih.gov); highlight the approved indication that applies to your case and include as an exhibit.
- Correct diagnosis codes: confirm the ICD-10 code on the original PA request matches an FDA-approved indication; if not, request a corrected submission from the prescriber's office before or alongside the appeal.
- Prescriber letter: states the specific FDA-approved indication, cites the label, and confirms the clinical diagnosis matches.
- If off-label: the prescriber letter must cite the applicable guideline organization and explain the evidence basis; reference Cigna's off-label coverage policy criteria directly.
## Criteria-Mapping Structure
| Denial Basis | Rebuttal | |---|---| | Drug not FDA-approved for submitted indication | FDA label excerpt showing approved indication; confirm ICD code alignment | | PA request listed incorrect indication code | Corrected PA with matching ICD-10 + prescriber attestation | | Off-label use lacks evidence support (if applicable) | Guideline organization citation + prescriber letter with evidence basis |
Before submitting, verify the exact approved indications in the current FDA prescribing label and cross-reference Cigna's current CGRP coverage policy. Both documents can change, and your appeal must respond to the versions currently in force.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →